BMRN Live signals | Maximize Profits with Getagraph.com

BUY 4477 min ago

@ $83.11

Issued: 1 May 2024 @ 15:32

Return: -0.80%

Previous signal: Apr 30 - 15:32

Previous signal: Sell

Return: 2.70 %

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:00):

Stats
Today's Volume	1.60M
Average Volume	1.57M
Market Cap	15.65B
EPS	$0 ( 2024-04-24 )
Next earnings date	( $0.570 ) 2024-07-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	77.77
ATR14	$2.27 (2.76%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-12	Bienaime Jean Jacques	Buy	20 000	Common Stock
2024-04-11	Bienaime Jean Jacques	Sell	20 000	Common Stock
2024-04-12	Bienaime Jean Jacques	Sell	20 000	Common Stock
2024-04-11	Bienaime Jean Jacques	Sell	20 000	Stock Option (Right to Buy Common Stock)
2024-04-12	Bienaime Jean Jacques	Sell	20 000	Stock Option (Right to Buy Common Stock)

INSIDER POWER
25.84
Last 93 transactions
Buy: 972 265 \| Sell: 563 201

Volume Correlation

Long: -0.79 (moderate negative)

Short: -0.97 (very strong negative)

Signal:(29) Possible Trading Opportunity Present (swing)

Biomarin Pharmaceutical Correlation

10 Most Positive Correlations
MMAC	0.923
RMRM	0.916
FREQ	0.89
ABST	0.889
IMPL	0.889
TTOO	0.887
SGBX	0.887
INFI	0.885
SBBP	0.884
CFV	0.884

10 Most Negative Correlations
APOP	-0.956
ICON	-0.907
RDUS	-0.893
MIND	-0.88
TRMD	-0.879
WRLD	-0.878
SYKE	-0.875
BNIXU	-0.873
SOUN	-0.873
MGTX	-0.873

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biomarin Pharmaceutical Correlation - Currency/Commodity

-0.62
( weak negative )

-0.65
( moderate negative )

0.00
( neutral )

-0.51
( weak negative )

0.23
( neutral )

0.47
( neutral )

Biomarin Pharmaceutical Financials

Annual	2023
Revenue:	$2.42B
Gross Profit:	$1.84B (76.15 %)
EPS:	$0.890

FY	2023
Revenue:	$2.42B
Gross Profit:	$1.84B (76.15 %)
EPS:	$0.890

FY	2022
Revenue:	$2.10B
Gross Profit:	$1.61B (76.92 %)
EPS:	$0.760

FY	2021
Revenue:	$1.85B
Gross Profit:	$1.38B (74.52 %)
EPS:	$-0.354

Financial Reports:

No articles found.

Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.